These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16252234)

  • 1. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.
    Pasmooij AM; Pas HH; Deviaene FC; Nijenhuis M; Jonkman MF
    Am J Hum Genet; 2005 Nov; 77(5):727-40. PubMed ID: 16252234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.
    Pasmooij AM; Nijenhuis M; Brander R; Jonkman MF
    J Invest Dermatol; 2012 May; 132(5):1374-83. PubMed ID: 22318390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.
    Jonkman MF; Scheffer H; Stulp R; Pas HH; Nijenhuis M; Heeres K; Owaribe K; Pulkkinen L; Uitto J
    Cell; 1997 Feb; 88(4):543-51. PubMed ID: 9038345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.
    Pasmooij AM; Pas HH; Bolling MC; Jonkman MF
    J Clin Invest; 2007 May; 117(5):1240-8. PubMed ID: 17476356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa.
    van den Akker PC; Pasmooij AMG; Joenje H; Hofstra RMW; Te Meerman GJ; Jonkman MF
    PLoS One; 2018; 13(2):e0192994. PubMed ID: 29470523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pigmentation and melanocyte supply to the epidermis depend on type XVII collagen.
    Gostyński A; Pasmooij AM; Del Rio M; Diercks GF; Pas HH; Jonkman MF
    Exp Dermatol; 2014 Feb; 23(2):130-2. PubMed ID: 24330315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel COL17A1 Compound Heterozygous Mutation in a Chinese Girl with Non-Herlitz Junctional Epidermolysis Bullosa.
    Yao YY; Zhang Y; Xie XH; Chen L; Zhu F; Zhou M
    Curr Med Sci; 2020 Aug; 40(4):795-800. PubMed ID: 32862392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the COL17A1 in non-Herlitz junctional epidermolysis bullosa and amelogenesis imperfecta.
    Nakamura H; Sawamura D; Goto M; Nakamura H; Kida M; Ariga T; Sakiyama Y; Tomizawa K; Mitsui H; Tamaki K; Shimizu H
    Int J Mol Med; 2006 Aug; 18(2):333-7. PubMed ID: 16820943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa.
    Darling TN; Yee C; Koh B; McGrath JA; Bauer JW; Uitto J; Hintner H; Yancey KB
    J Invest Dermatol; 1998 Feb; 110(2):165-9. PubMed ID: 9457913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.
    Umegaki-Arao N; Pasmooij AM; Itoh M; Cerise JE; Guo Z; Levy B; Gostyński A; Rothman LR; Jonkman MF; Christiano AM
    Sci Transl Med; 2014 Nov; 6(264):264ra164. PubMed ID: 25429057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy.
    Bauer JW; Lanschuetzer C
    Clin Exp Dermatol; 2003 Jan; 28(1):53-60. PubMed ID: 12558632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation.
    Darling TN; Yee C; Bauer JW; Hintner H; Yancey KB
    J Clin Invest; 1999 May; 103(10):1371-7. PubMed ID: 10330419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features of epidermolysis bullosa simplex due to mutations in the ectodomain of type XVII collagen.
    Pasmooij AM; van der Steege G; Pas HH; Smitt JH; Nijenhuis AM; Zuiderveen J; Jonkman MF
    Br J Dermatol; 2004 Sep; 151(3):669-74. PubMed ID: 15377356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autosomal dominant junctional epidermolysis bullosa.
    Almaani N; Liu L; Dopping-Hepenstal PJ; Lovell PA; Lai-Cheong JE; Graham RM; Mellerio JE; McGrath JA
    Br J Dermatol; 2009 May; 160(5):1094-7. PubMed ID: 19120338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
    Pasmooij AM; Garcia M; Escamez MJ; Nijenhuis AM; Azon A; Cuadrado-Corrales N; Jonkman MF; Del Rio M
    J Invest Dermatol; 2010 Oct; 130(10):2407-11. PubMed ID: 20574443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation.
    Mabuchi E; Umegaki N; Murota H; Nakamura T; Tamai K; Katayama I
    Br J Dermatol; 2007 Sep; 157(3):596-8. PubMed ID: 17596158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen XVII.
    Has C; Kern JS
    Dermatol Clin; 2010 Jan; 28(1):61-6. PubMed ID: 19945617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex.
    Huber M; Floeth M; Borradori L; Schäcke H; Rugg EL; Lane EB; Frenk E; Hohl D; Bruckner-Tuderman L
    J Invest Dermatol; 2002 Jan; 118(1):185-92. PubMed ID: 11851893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa.
    Kiritsi D; Kern JS; Schumann H; Kohlhase J; Has C; Bruckner-Tuderman L
    J Med Genet; 2011 Jul; 48(7):450-7. PubMed ID: 21357940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by outsplicing of mutated exon 30 coding for the COL15 domain.
    Pasmooij AM; van Zalen S; Nijenhuis AM; Kloosterhuis AJ; Zuiderveen J; Jonkman MF; Pas HH
    Exp Dermatol; 2004 Feb; 13(2):125-8. PubMed ID: 15009107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.